Should You Worry About the Short Interest in Merrimack (MACK)?

Many investors appear to be quite bearish Merrimack Pharmaceuticals Inc (MACK) especially if you look at the percentage of the float that is sold short for this stock. Currently, 20.8% of the float is sold short, suggesting an extreme level of bearishness for MACK.

However, it is worth noting that earnings estimates have actually been moving higher for the company, despite the pessimism. Thanks to these rising estimates, we actually have a Zacks Rank #2 (Buy) on MACK, so we clearly don’t believe in the negativity surrounding this firm, and are instead looking for shares of MACK to move higher in the weeks ahead.

MERRIMACK PHARMACEUTICALS INC (MACK): Free Stock Analysis Report


Zacks Investment Research